Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet

Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top